Suggested Remit: To appraise the clinical and cost effectiveness of elotuzumab in combination with pomalidomide and low-dose dexamethasone within its marketing authorisation for treating relapsed and refractory multiple myeloma.
Following on from information provided to NICE by the company in September 2018, the appraisal of Multiple myeloma - elotuzumab (with pomalidomide and dexamethasone, after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1467
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2018, the appraisal of Multiple myeloma - elotuzumab (with pomalidomide and dexamethasone, after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 September 2018 | Suspended. Suspended |
| 28 August 2018 - 25 September 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 18 September 2018 | Note added to the project documents |
| 13 February 2018 | Referral |
| 13 February 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual